Upon joining the study, the first step involves attending an initial visit where the informed consent form is signed and dated. This form confirms understanding and agreement to participate in the study.

During this visit, eligibility is confirmed, ensuring the participant is over 18 years old and scheduled for a coronary angiography to assess coronary artery disease.

Participants must be capable of undergoing stress imaging protocols, which may involve either pharmacological or exercise stress tests.

For females of reproductive potential, effective contraception must be used for at least one month prior to screening and continued during the study and for one week after the last administration of the investigational medicinal product (IMP). Males must use effective contraception for three months after the last IMP exposure.

The study involves the administration of three medications: SYN2, Adenosine (6 mg/2 ml solution for injection), and Rapiscan (400 microgram solution for injection).

These medications are administered as solutions for injection, with the specific purpose of aiding in the imaging process to assess coronary artery disease.

Participants undergo a positron emission tomography (PET) scan using the novel tracer SYN2. This imaging technique helps in diagnosing coronary artery disease by evaluating the heart’s blood flow.

The diagnostic performance of the SYN2 PET scan is assessed against a reference standard to determine its effectiveness in detecting significant coronary artery disease.

Throughout the study, participants are monitored for any adverse events, including changes in laboratory parameters, ECG parameters, physical examination, and vital signs.

The study aims to evaluate the sensitivity and specificity of the SYN2 PET scan in detecting coronary artery disease, with results compared to the reference standard.